NCT03611712 - PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

February 3, 2023

Study Completion Date

March 5, 2025

Conditions

Cancer-related FatigueSurvivalTumor, Esophageal

Interventions

DRUG

Astragalus Polysaccharides 500 mg

PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)

Trial Locations (4)

104

Mackay Memorial Hospital, Taipei

114

Tri-Service General Hospital, Taipei

220

Far Eastern Memorial Hospital, Taipei

235

Taipei Medical University -Shung Ho Hospital, Taipei